|
102 Companies |
|
136 Products |
|
136 Products |
|
123 Mechanisms of Action |
|
5 Trials |
|
1111 News |
|
| «12...567891011121314151617» |
- | rivaroxaban / Generic mfg.
New P4 trial: Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer (clinicaltrials.gov) - Nov 19, 2013
P4, N=127, Recruiting, Sponsor: Seoul National University Hospital
- ||||| Humira (adalimumab) / AbbVie
Trial initiation date: APPRECIA: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn (clinicaltrials.gov) - Nov 14, 2013
P3, N=84, Active, not recruiting, Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Initiation date: Dec 2011 --> Jun 2012
- Trial initiation date: ARMCENVIN: Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=216, Recruiting, Sponsor: Assistance Publique - H
Initiation date: Dec 2011 --> Jun 2012 Initiation date: Feb 2009 --> Feb 2010
- Enrollment change: SANIBA: Off- Loading Shoe to Improve Healing and Prevention of Recurrence of Neuropathic Diabetic Plantar Foot Ulcers (clinicaltrials.gov) - Nov 12, 2013
P3, N=33, Completed, Sponsor: Assistance Publique - H
Initiation date: Feb 2009 --> Feb 2010 N=64 --> 33
- Trial completion: SANIBA: Off- Loading Shoe to Improve Healing and Prevention of Recurrence of Neuropathic Diabetic Plantar Foot Ulcers (clinicaltrials.gov) - Nov 12, 2013
P3, N=33, Completed, Sponsor: Assistance Publique - H
N=64 --> 33 Recruiting --> Completed
- Trial completion, Surgery, Biopsy: Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (clinicaltrials.gov) - Nov 12, 2013
P2, N=2, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed Active, not recruiting --> Completed
- Trial initiation date: FACBC for Recurrent Prostate Cancer (clinicaltrials.gov) - Nov 6, 2013
P2, N=25, Recruiting, Sponsor: David M. Schuster, MD
Active, not recruiting --> Completed Initiation date: Apr 2013 --> Nov 2013
- New P2 trial: Potassium Citrate Supplementation vs. Dietary Counseling (clinicaltrials.gov) - Nov 6, 2013
P2, N=50, Recruiting, Sponsor: University of North Carolina, Chapel Hill
- Muphoran (fotemustine) / Servier, Zelboraf (vemurafenib) / Roche
New P2 trial, Metastases: BeyPro1: Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib (clinicaltrials.gov) - Nov 5, 2013
P2, N=31, Active, not recruiting, Sponsor: Paola Queirolo
- Muphoran (fotemustine) / Servier, Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: BeyPro1: Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib (clinicaltrials.gov) - Nov 5, 2013
P2, N=31, Active, not recruiting, Sponsor: Paola Queirolo
Initiation date: Apr 2013 --> Nov 2013 Not yet recruiting --> Active, not recruiting
- chloroquine phosphate / Generic mfg.
Enrollment closed: CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS (clinicaltrials.gov) - Nov 3, 2013
P4, N=62, Active, not recruiting, Sponsor: University of Sao Paulo General Hospital
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- HepaGam B (hepatitis B immune globulin intravenous (human)) / Kamada
Enrollment change, Combination therapy: Evaluation of HepaGam B (clinicaltrials.gov) - Oct 29, 2013
P4, N=9, Completed, Sponsor: Cangene Corporation
Not yet recruiting --> Active, not recruiting N=31 --> 9
- cisplatin / Generic mfg., sirolimus / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, Surgery: Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery (clinicaltrials.gov) - Oct 29, 2013
P1, N=13, Recruiting, Sponsor: Mayo Clinic
N=31 --> 9 Not yet recruiting --> Recruiting
- HepaGam B (hepatitis B immune globulin intravenous (human)) / Kamada
Trial completion, Combination therapy: Evaluation of HepaGam B (clinicaltrials.gov) - Oct 29, 2013
P4, N=9, Completed, Sponsor: Cangene Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P2 trial: Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection (clinicaltrials.gov) - Oct 28, 2013
P2, N=46, Recruiting, Sponsor: MemorialCare Health System
- |||| VivaGel (astodrimer vaginal) / Starpharma
Trial completion: Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV) (clinicaltrials.gov) - Oct 26, 2013
P2, N=205, Completed, Sponsor: Starpharma Pty Ltd
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis. (clinicaltrials.gov) - Oct 23, 2013
P=N/A, N=16, Terminated, Sponsor: Spirig Pharma Ltd.
Active, not recruiting --> Completed Recruiting --> Terminated; sponsor decision
- Enrollment change: Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis. (clinicaltrials.gov) - Oct 23, 2013
P=N/A, N=16, Terminated, Sponsor: Spirig Pharma Ltd.
Recruiting --> Terminated; sponsor decision N=80 --> 16
- Trial withdrawal, Gene therapy: Gene Therapy for Prostate Cancer That Returns After Radiation Therapy (clinicaltrials.gov) - Oct 22, 2013
P1, N=0, Withdrawn, Sponsor: Simon Hall
N=80 --> 16 Recruiting --> Withdrawn
- Enrollment change, Gene therapy: Gene Therapy for Prostate Cancer That Returns After Radiation Therapy (clinicaltrials.gov) - Oct 22, 2013
P1, N=0, Withdrawn, Sponsor: Simon Hall
Recruiting --> Withdrawn N=24 --> 0
- ||| Cysview (hexaminolevulinate) / Photocure
Trial completion: Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB (clinicaltrials.gov) - Oct 21, 2013
P=N/A, N=551, Completed, Sponsor: PhotoCure
N=24 --> 0 Recruiting --> Completed
- | escitalopram / Generic mfg.
Enrollment open, Head-to-Head: Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial (clinicaltrials.gov) - Oct 14, 2013
P3, N=240, Recruiting, Sponsor: University of Sao Paulo
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change, Surgery, Biopsy: Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (clinicaltrials.gov) - Oct 10, 2013
P2, N=2, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting N=25 --> 2
- | tasadenoturev (DNX-2401) / DNAtrix
New P1 trial, Oncolytic virus: D24GBM: Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (clinicaltrials.gov) - Oct 6, 2013
P1, N=31, Recruiting, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
- ||| imatinib / Generic mfg.
Enrollment closed, Stroma: Five Year Adjuvant Imatinib Mesylate (Gleevec (clinicaltrials.gov) - Oct 5, 2013
P2, N=91, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=25 --> 2 Recruiting --> Active, not recruiting
- ||| Trial completion, HEOR: Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational (clinicaltrials.gov) - Sep 29, 2013
P=N/A, N=855, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open: Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence (clinicaltrials.gov) - Sep 26, 2013
P2, N=36, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- chloroquine phosphate / Generic mfg., primaquine / Generic mfg.
Enrollment open: Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan (clinicaltrials.gov) - Sep 24, 2013
P=N/A, N=50, Recruiting, Sponsor: Menzies School of Health Research
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | chloroquine phosphate / Generic mfg.
New P4 trial: CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS (clinicaltrials.gov) - Sep 23, 2013
P4, N=62, Active, not recruiting, Sponsor: University of Sao Paulo General Hospital
- filorexant (MK6096) / Merck (MSD)
Trial termination, Monotherapy: Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022) (clinicaltrials.gov) - Sep 19, 2013
P2a, N=129, Terminated, Sponsor: Merck
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Low Enrollment
- filorexant (MK6096) / Merck (MSD)
Enrollment change, Monotherapy: Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022) (clinicaltrials.gov) - Sep 19, 2013
P2a, N=129, Terminated, Sponsor: Merck
Active, not recruiting --> Terminated; Low Enrollment N=326 --> 129
- | Trial completion, Surgery: Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer (clinicaltrials.gov) - Sep 18, 2013
P2/3, N=284, Completed, Sponsor: University of Illinois at Chicago
N=326 --> 129 Recruiting --> Completed
- | CombiPatch (estradiol/norethindrone acetate) / Novartis
Trial completion: Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer (clinicaltrials.gov) - Sep 18, 2013
P3, N=1300, Completed, Sponsor: Regional Oncologic Center
Recruiting --> Completed Active, not recruiting --> Completed
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Enrollment closed: Herbal Therapy for Treatment of Recurrent Prostate Cancer (clinicaltrials.gov) - Sep 5, 2013
P2, N=45, Active, not recruiting, Sponsor: University of Southern California
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Biomarker, Trial termination: Risk Factors and Biomarkers Associated With Recurrence After Excision of Primary Pterygium (clinicaltrials.gov) - Aug 31, 2013
P=N/A, N=1, Terminated, Sponsor: Singapore National Eye Centre
Recruiting --> Active, not recruiting Recruiting --> Terminated; Other and future studies on lipiview in pterygium will cover this current trial sufficiently.
- Biomarker, Enrollment change: Risk Factors and Biomarkers Associated With Recurrence After Excision of Primary Pterygium (clinicaltrials.gov) - Aug 31, 2013
P=N/A, N=1, Terminated, Sponsor: Singapore National Eye Centre
Recruiting --> Terminated; Other and future studies on lipiview in pterygium will cover this current trial sufficiently. N=100 --> 1
- Biomarker, Trial completion: Diet and Exercise or Normal Care in Overweight or Obese Women Who Have Undergone Treatment for Stage I, Stage II, or Stage III Breast Cancer (clinicaltrials.gov) - Aug 22, 2013
P=N/A, N=100, Completed, Sponsor: Sheffield Hallam University
N=100 --> 1 Recruiting --> Completed
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment change: Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States (clinicaltrials.gov) - Aug 21, 2013
P2, N=24, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed N=40 --> 24
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment closed: Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States (clinicaltrials.gov) - Aug 21, 2013
P2, N=24, Active, not recruiting, Sponsor: Gilead Sciences
N=40 --> 24 Enrolling by invitation --> Active, not recruiting
- Trial completion, MRI: Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis (clinicaltrials.gov) - Aug 20, 2013
P=N/A, N=29, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Enrolling by invitation --> Active, not recruiting Recruiting --> Completed
- ||| rivaroxaban / Generic mfg.
Enrollment open: Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (clinicaltrials.gov) - Aug 8, 2013
P=N/A, N=150, Recruiting, Sponsor: Bayer
Recruiting --> Completed Not yet recruiting --> Recruiting
- colchicine / Generic mfg.
Trial completion: CORP 2: Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment. (clinicaltrials.gov) - Aug 5, 2013
P4, N=240, Completed, Sponsor: Azienda Sanitaria Locale 3, Torino
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- ||||| Cysview (hexaminolevulinate) / Photocure
Enrollment change: A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer (clinicaltrials.gov) - Aug 4, 2013
P3, N=233, Completed, Sponsor: PhotoCure
Not yet recruiting --> Completed N=164 --> 233
- Trial completion: SPIRITDZSM1: The Secondary Prevention Trial for Ischemic Stroke With DengzhanShengmai Capsule (clinicaltrials.gov) - Aug 4, 2013
P4, N=3143, Completed, Sponsor: Guangzhou University of Traditional Chinese Medicine
N=164 --> 233 Recruiting --> Completed
- ||||||| Cysview (hexaminolevulinate) / Photocure
Trial completion: A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer (clinicaltrials.gov) - Aug 4, 2013
P3, N=233, Completed, Sponsor: PhotoCure
Recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal, Metastases: Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer (clinicaltrials.gov) - Aug 1, 2013
P1, N=0, Withdrawn, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- Enrollment closed: ITEP: Impact of PET Scan on the Curative Strategy of Colo-rectal Cancers : A Randomized Study (clinicaltrials.gov) - Jul 31, 2013
P=N/A, N=240, Active, not recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Withdrawn Recruiting --> Active, not recruiting
- Enrollment change: AXIL95: Surgical Breast Resection With or Without Axillary Lymph Node Excision in Treating Women With Breast Cancer (clinicaltrials.gov) - Jul 24, 2013
P3, N=592, Terminated, Sponsor: Institut Bergoni
Recruiting --> Active, not recruiting N=1612 --> 592
- |||||| Civacir (hepatitis C immune globulin) / ADMA Biologics, Kedrion
Enrollment open: Civacir (clinicaltrials.gov) - Jul 11, 2013
P3, N=90, Recruiting, Sponsor: Biotest Pharmaceuticals Corporation
N=1612 --> 592 Not yet recruiting --> Recruiting
- | New P2 trial: Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors (clinicaltrials.gov) - Jul 10, 2013
P2, N=140, Recruiting, Sponsor: michal roll